Literature DB >> 19344049

Buprenorphine: a review.

Sidarth Wakhlu1.   

Abstract

A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000), signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of their practice. Two years later, on October 8, 2002, Suboxone (Buprenorphine/Naloxone) and Subutex (Buprenorphine) received FDA approval for the treatment of opioid addiction. Prior to DATA 2000, opioid maintenance treatment was available through highly regulated methadone clinics. This article discusses opioid addiction in the United States today and the principles of buprenorphine therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344049     DOI: 10.5055/jom.2009.0007

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  4 in total

Review 1.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

2.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

3.  Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration.

Authors:  Elizabeth Weesner; Hosain Ghassemi; Iryna Salapenka; Jaya Sri Konakanchi; Gregory Maggio; Roopa Sethi
Journal:  Kans J Med       Date:  2022-08-22

4.  Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.

Authors:  Sylvia Fitting; Shiping Zou; Nazira El-Hage; Masami Suzuki; Jason J Paris; Christina J Schier; José W Rodríguez; Myosotys Rodriguez; Pamela E Knapp; Kurt F Hauser
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.